Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, and operation of biological products in China. It offers freeze-dried human rabies vaccines; ACYW135 meningococcal polysaccharide vaccine. The company was founded in 2004 and is based in Chengdu, China.
Frequently asked questions
What sector does Chengdu Kanghua Biological Products (300841) operate in?
Chengdu Kanghua Biological Products belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Chengdu Kanghua Biological Products (300841) current stock price?
As of the latest data, Chengdu Kanghua Biological Products stock price is CN¥49.10, with a previous close of CN¥48.50. Chengdu Kanghua Biological Products gained CN¥0.60 in the last trading session, representing a 1.24% increase.
What is Chengdu Kanghua Biological Products (300841) current market capitalization?
Chengdu Kanghua Biological Products market cap is approximately 6.38 billion.
What is Chengdu Kanghua Biological Products (300841) Earnings Per Share (EPS)?
The trailing EPS is CN¥1.74, and the forward EPS is CN¥2.45.
What is Chengdu Kanghua Biological Products (300841) Price-to-Earnings (P/E) ratio?
Chengdu Kanghua Biological Products current P/E ratio is 28.22, with a forward P/E of 20.04.
Does Chengdu Kanghua Biological Products (300841) pay dividends?
Yes. Chengdu Kanghua Biological Products pays annual dividends with an annualized yield of 1.02% and an estimated annual payout of CN¥0.50 per share.
When is the next ex-dividend date for Chengdu Kanghua Biological Products (300841)?
The next ex-dividend date is scheduled for May 29, 2027.
What is Chengdu Kanghua Biological Products (300841) beta (volatility) score?
Chengdu Kanghua Biological Products has a beta of 0.442, indicating lower volatility than the overall market.
